• Collaboration leverages DualityBio's proprietary DUPAC payload platform and early global clinical development capabilities, with Genentech assuming further clinical development and global commercialization
  • DUPAC, one of the DualityBio's four proprietary ADC technology platforms, comprises multiple payloads with novel mechanism of action designed to address resistance to the payload classes underlying currently approved ADCs
  • DualityBio to receive a US$45 million upfront payment, more than US$1 billion in potential milestone payments, and tiered royalties on net sales

SHANGHAI, Aug. 28, 2026 /PRNewswire/ -- DUALITYBIO Inc. (HKEX: 09606; "DualityBio" or the "Company") today announced that it has entered into a collaboration and license agreement with Genentech, a member of the Roche Group, to develop next-generation antibody-drug conjugates ("ADCs") built on the Company's proprietary DualityBio Unique Payload Antibody Conjugate ("DUPAC") platform.

(0) comments

Welcome to the discussion.

Keep it Clean. Please avoid obscene, vulgar, lewd, racist or sexually-oriented language.
PLEASE TURN OFF YOUR CAPS LOCK.
Don't Threaten. Threats of harming another person will not be tolerated.
Be Truthful. Don't knowingly lie about anyone or anything.
Be Nice. No racism, sexism or any sort of -ism that is degrading to another person.
Be Proactive. Use the 'Report' link on each comment to let us know of abusive posts.
Share with Us. We'd love to hear eyewitness accounts, the history behind an article.